KRAS G12V
Clinical trials for KRAS G12V explained in plain language.
Never miss a new study
Get alerted when new KRAS G12V trials appear
Sign up with your email to follow new studies for KRAS G12V, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets multiple KRAS mutations in advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called BBO-11818 in people with advanced cancers that have specific KRAS gene mutations. The study aims to find a safe dose and see if the drug can shrink tumors in cancers like lung, pancreatic, and colorectal cancer. Participants wil…
Matched conditions: KRAS G12V
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New pill targets 'Undruggable' cancer mutations in major trial
Disease control Recruiting nowThis study is testing a new oral drug, S241656, alone and in combination with other cancer therapies. It aims to find a safe and effective dose for adults with advanced cancers, including lung, pancreatic, and colorectal cancers, that have specific genetic mutations like KRAS or …
Matched conditions: KRAS G12V
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for pancreatic cancer patients: experimental immunotherapy offered outside clinical trial
Disease control AVAILABLEThis program provides access to an experimental immunotherapy called ELI-002 7P for patients with a specific type of pancreatic cancer (with KRAS or NRAS mutations) who are at high risk of the cancer coming back after surgery. It is for patients who have no other good treatment o…
Matched conditions: KRAS G12V
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC